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Background: A combination of psychosocial interventions and medications has been highly recommended as a
successful treatment package for schizophrenia. Its cost-effectiveness has not been fully explored yet. The aim of
the present analysis was to evaluate the cost-effectiveness of antipsychotics combined with psychosocial treatment
and treatment as usual for patients with early-stage schizophrenia.
Method: Patients with schizophrenia (N = 1, 268) were assigned to the combination of medication and
psychosocial intervention or treatment as usual for up to 12 months. Cost analysis included direct medical costs,
direct nonmedical costs and indirect costs. Quality-adjusted life year (QALY) ratings were assessed with Short- Form 6D.
Results: Average monthly psychosocial intervention costs for combined treatment were higher than treatment as
usual (p = 0.005), but no significant differences were found in direct costs, indirect costs, and total costs between two
groups (all p-values≥ 0.556). Combined treatment was associated with significant higher QALY ratings than treatment
as usual (p = 0.039). Compared with treatment as usual, combined treatment resulted in a gain of 0.031 QALY ratings at
an additional cost of US$ 56.4, yielding an incremental cost-effectiveness ratio of US$ 1819.4 per QALY gained.
Conclusions: Despite some limitations, our results supported that medication combined with psychosocial treatment
was more cost-effective than treatment as usual for patients with early-stage schizophrenia.
Trial registration: clinicaltrials.gov Identifier: NCT00654576
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Schizophrenia is a severe and chronic illness as well as
one of the most expensive illnesses to treat [1,2], which
has a significant impact on individuals, families and soci-
eties in terms of both health and economic loss. Schizo-
phrenia is also among the 15 leading causes of disability
and the top 10 leading causes of years lost due to dis-
ability [3]. In China, there are about 10 million patients
suffering from schizophrenia, and it is estimated that the
annual economic cost of schizophrenia exceeds 1 billion
RMB [4,5].* Correspondence: xfguocsu@163.com; fengcsu@yahoo.com.cn
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unless otherwise stated.Although antipsychotic medications are the main-
stay of the treatment for schizophrenia, patients with
schizophrenia benefit more from the combined use of
antipsychotic drugs and psychosocial treatment than phar-
macotherapy alone in delaying or preventing relapse or
reducing hospital days [7,8]. Symptomatic relapse or re-
admission in schizophrenia is both distressing and costly.
It can devastate the lives not only of patients, but also of
their families [9].
Most economic evidence in this area focuses on the
cost-effectiveness of medications and different ways of
organizing mental health care [10-12], and there is still
little economic evidence on psychosocial intervention
[13,14]. In a previous article, we reported a 1-year
randomized clinical trial that examined the effect of
medication combined with psychosocial intervention vsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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early stage schizophrenia [15].
The current article presents resulted on measures of
health care costs and health related quality of life. The
primary outcomes were total health costs and quality-
adjusted life year (QALY) ratings. Based on a randomized
controlled trial, the present study sought to examine whe-
ther medication combined psychosocial intervention rep-
resents a more cost-effective intervention than treatment
as usual for patients with early stage schizophrenia.
Methods
Study design
The trial was a multicenter, randomized, and controlled
study conducted between January 2005 and October
2007 at 10 clinical sites in China. The background, ra-
tionale, and methods of the Early-stage Schizophrenia
Outcome Study (ESOS) have been presented in detail
previously [15]. This study was approved by the insti-
tutional review board at the Second Xiangya Hospital,
Chongqing Mental Health Center, Psychiatric Hospital of
Jiangxi Province, West China Hospital, Mental Hospital
of Henan Province, Beijing Anding Hospital, Shanghai
Mental Health Center, Guangzhou Brain Hospital, Hunan
Brain Hospital, and Nanjing Brain Hospital. Written in-
formed consent was obtained from the patients or their
legal guardians. Additional files 1 and 2 comprise the
the full trial protocol and consort statement extension
for cluster randomized controlled trials respectively.
Participants were randomly assigned to receive the
combination of medication and psychosocial treatment
or treatment as usual (medication treatment and brief
intervention) and were monitored for up to 12 months
or until medication treatment was discontinued for any
reason after baseline assessment. Group assignment was
based on a 1:1 randomization scheme balanced by sites
and medication prescribed by independent investigator
according to a computer generated randomization list.
Participants
Study participants were enrolled from outpatient psychi-
atric clinics and under maintenance treatment. Inclusion
criteria in this study were: (1) age 18 to 50 years old; (2)
met DSM-IV diagnostic criteria for schizophrenia or
schizophreniform disorder, as determined by the Struc-
tured Clinical Interview for DSM-IV Axis I Disorders–
Clinician Version administered by study investigators
[16]; (3) length of illness ≤ 5 years; (4) stable clinical condi-
tion (Positive and Negative Syndrome Scale PANSS, [17]
total scores ≤60); (5) treated with one of the following
7 oral antipsychotics: chlorpromazine, sulpiride, cloza-
pine, risperidone, olanzapine, quetiapine or aripipra-
zole. Patients were excluded if they were: (1) prescribed
two or more antipsychotics or long-acting injectableantipsychotics; (2) participating in other therapy pro-
grams; (3) pregnant or breastfeeding; or (4) having serious
and unstable medical condition.
Intervention
All patients continued taking the original antipsychotic
during the 12-month follow-up period. If a patient’s
medication was stopped or switched, patients were clas-
sified as discontinued and terminated from the study.
The psychosocial intervention was reported in detail
elsewhere [15]. In brief, patients who were assigned
to the combined treatment group received medication
treatment and were enrolled in a psychosocial interven-
tion program. The psychosocial intervention included 4
evidence-based practices: psychoeducation, family inter-
vention, skills training, and cognitive behavior therapy was
conducted monthly for 12 months. Participants received
the 4 interventions on the same day, for a total of 48 one-
hour sessions. A lunch break and 2 half-hour breaks were
provided to maintain engagement and attention. Thera-
pists who had at least 2 years of clinical experience after
earning an MD or PhD or at least 5 years of experience
after earning a masters degree in clinical psychology deliv-
ered the psychosocial intervention.
The brief intervention included case management with
antipsychotic medication and supportive interventions,
which were provided monthly for 12 months.
Measuring service use and costs
Costs estimates included direct medical costs, direct
nonmedical costs, and indirect nonmedical costs. Direct
medical costs consisted of intervention costs such as me-
dication tests, therapy and so on, and uptake of health
care services, including costs of medication. Service use
was documented through a questionnaire completed by
the caregiver at the end of every month during the study.
Costs were calculated in US dollar ($) for the reference
year 2005 in China.
The costs of psychosocial interventions consisted of
start-up costs (development and training) and ongoing
costs (services, supplies, travel and salary). We assumed
that the psychosocial intervention protocol would be
prepared by 2 specialists for 120 hours each and a train-
ing program would be conducted for 40 clinicians from
all 10 psychiatric hospitals. The intervention program
would consist of 42-hour sessions by two therapists [15].
We assumed that each session would have 12 partici-
pants (6 patients and 6 family carers). The unit cost for
each medical procedure was calculated from the price
system database built by the National Development and
Reform Commission of China [18]. Direct nonmedical
costs consisted of costs for traveling and parking. These
costs were valued at US $ 0.1 per kilometer and US $ 0.5
per hour parking time.
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ses occur due to illness. Production losses can occur un-
der 3 conditions. Patients were absent from paid work
due to sick leave (work loss days), or they were ill but
continue to work with reduced efficiency (work cutback
days), or caregivers were absent from paid work due to
take care of patients.
Cost-effectiveness analysis requires a single measure of
health related quality of life that reflects both health gains
and health losses. Participants were asked to complete
Medical Outcome Study Short-Form 36-item question-
naire (SF-36) [19] at baseline, 6 months, and 12 months.
The utility scores of the SF-6D derived from responses to
eleven questions on the SF-36 questionnaire are used to
calculate the QALYs gained during the follow-up period
by weighing the length of time spent in a particular health
condition by the utility. The SF-6D has 6 dimensions
(physical functioning, role limitations, social functioning,
pain, mental health and vitality) which have from 4 to 6
levels of severity [20]. The SF-6D scoring algorithm has
been validated and established for the adult Chinese popu-
lation in Hong Kong in previous studies [21,22]. The gen-
eral population mean SF-6D preference value is 0.787,1563 Scre
1268 Rand
633 Assigned to combined   
treatment
29 Did not take psychosocial 
intervention
580 Included in primary 
analysis
24 Excluded owing to
missing data
406 Completed 1-y interview
88 Clinical relapse
71 Loss to follow-up
34 Owing to nonadherence 
to drugs
5 Owing to intolerability 
Figure 1 Flowchart of participation in the study.which was estimated from the SF-36 data of a general
population survey of 2410 adult Chinese in Hong Kong in
1998 [23].
Other outcomes further assessed treatment effective-
ness by measuring rates of treatment discontinuation,
symptom severity (PANSS) [17] and global severity of
illness (Clinical Global Impressions Scale) [24]. The social
functioning and family burden were rated by the Global
Assessment Scale (GAS) [25] and Family Burden Scale
(FBS) [26], respectively. Agreement among the raters was
high for the PANSS, CGI and GAS (Pearson correlation
coefficient, 0.78-0.86) at baseline and every 6 months. All
raters were kept blind for patient's treatment condition.
Statistical analysis
All analyses were conducted with the Statistical Package
for Social Sciences, version 15.0 (SPSS Inc, Chicago,
Illinois). Baseline characteristics were compared between
the two groups by analysis of variance, Pearson’s chi-
square test, or Fisher’s exact test, as appropriate. Average
monthly costs were compared between the groups with
use of a mixed model including the same fixed covariates
as for the time to discontinuation, plus baseline value,ened
295 Excluded




635 Assigned to treatment as 
usual 
604 Included in primary
analysis
31 Excluded owing to 
missing data
338 Completed 1-y interview
143 Clinical relapse
90 Loss to follow-up
55 Owing to nonadherence 
to drugs
9 Owing to intolerability 
Table 1 Patient characteristics at the time of random








Age, y 26.1(7.6) 26.3(8.0) 0.237 0.626
Male No.(%) 312(53.8) 336(55.6) 0.403 0.526
Marital status No.(%) 3.113 0.211
Married 143(24.7) 164(27.2)
Previously married 37(6.4) 26(4.3)
Never married 400(69.0) 414(68.5)
Education, y 12.2(2.9) 11.9(2.9) 2.564 0.110
Duration of schizophrenia, mo 22.5(20.0) 24.7(21.0) 3.462 0.063
PANSS total score 44.6(13.5) 45.3(13.9) 0.799 0.372
CGI severity score 2.5(1.2) 2.6(1.2) 0.849 0.357
GAS total score 74.2(11.8) 74.2(11.9) 0.000 0.984
FBS total score 12.3(7.6) 12.6(7.9) 0.468 0.494
SF-36
PCS 49.6(7.4) 51.0(16.6) 3.621 0.057
MCS 50.3(10.5) 49.4(12.5) 1.617 0.204
PANSS = Positive and Negative Syndrome Scale; CGI = Clinical Global
Impressions Scale; GAS = Global Assessment Scale; FBS = family burden scale of
diseases; SF-36 = the 36-Item Short Form Health Survey; PCS = the Physical
Component Score; MCS = the Mental Component Score.
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was classified into months (baseline, 3, 6, 9, and 12
months). All statistical tests were two-tailed.
In the cost-effectiveness analysis, the average benefit
in terms of Quality adjusted life year (QALY) gained and
the average cost was calculated for each treatment. The
average cost-effectiveness ratio (CER) of each treat-
ment was obtained. We measured the incremental cost-
effectiveness ratio (ICER), defined as extra cost per QALY
gained [14,27] with the combined medication and psycho-
social intervention (Combined treatment) and treatment
as usual (TAU).
ICER ¼ CostCombined treatment − CostTAUð Þ=
EffectCombined treatment − EffectTAUð Þ
A strategy was considered as cost-effective versus treat-
ment as usual when ICERs were below the cost-utility
threshold acceptable in China. We used 3 × the per capita
GDP of China in 2005 (US $ 5,100)/QALY as the thresh-
old according to WHO recommendation [28,29].
Sensitivity analysis
In this study, one-way deterministic analysis was carried
out to test the model’s robustness. One-way determi-
nistic analysis included modifications of the following
inputs: the number of subjects per workshop that was
varied from 5 to 3, and the clinical effect and the cost of
per workshop that were varied by ± 20%. The psycho-
social intervention workshops were designed to be deliv-
ered to 6 patients, and the total cost of providing the
intervention is the same even if fewer subjects attend.
The per-person cost of the intervention therefore varies
depending on the number of subjects per workshop. As-
suming that the effectiveness of the intervention was the
same, we decreased the number of subjects per work-
shop in sensitivity analysis.
Results
Participants
Altogether, 1268 participants entered the study, 633 were
assigned to receive antipsychotics combined with psycho-
social intervention (of whom 29 refused the psychosocial
intervention) and 635 to receive treatment as usual. Base-
line utilization data were not available for 55, leaving 1184
patients for analysis (Figure 1).
There were no significant differences between study
groups with respect to baseline demographic and clin-
ical characteristics (all p-values ≥ 0.057). The mean age
was 26 years, and 55 percent of the patients were male
(Table 1).
In the intention-to-treat analysis using all available
follow-up data, 62.8% of patients completed 1-year evalu-
ation, with significant differences in the proportion ofparticipants in two treatments groups (70.0% for com-
bined treatment group and 56.0% for treatment as usual
group, χ2 = 24.975, df = 1, p < 0.001).
Costs
Average monthly costs by treatment groups were showed
in Table 2. The majority costs were attributable to the dir-
ect costs. Average monthly psychosocial intervention costs
were higher for combined treatment than treatment as
usual (p = 0.005), but no significant differences were found
in direct costs, indirect costs, and total costs between two
groups (all p-values ≥ 0.556).
Effectiveness
As shown in Figure 2, significant improvement in QALY
ratings was found from baseline to 12 months. Com-
bined treatment was associated with higher QALY rat-
ings than treatment as usual (p = 0.039). Table 3 reported
mixed model-adjusted means of the effectiveness mea-
sured by treatment groups across months 6 and 12. Differ-
ences between two treatment groups were also observed
in FBS total scores and SF-36 the Physical Component
Score (PCS) and the Mental Component Score (MCS)
scores (all p-values ≤ 0.042).
Compared with treatment as usual, combined treatment
resulted in a gain of 0.031 QALYs at an additional cost
of US$ 56.4, yielding an incremental cost-effectiveness
ratio of US$ 1819.4 per QALY gained. Considering the
Table 3 Comparison of effectiveness by Treatment









QALYs 0.676(0.004) 0.658(0.004) 3.259 0.039
SF-36
PCS 50.6(0.3) 50.3(0.2) 4.650 0.010
MCS 51.5(0.3) 49.1(0.3) 3.643 0.026
FBS 8.6(0.2) 10.1(0.2) 2.484 0.042
PANSS total scores 38.5(0.2) 40.0(0.2) 0.406 0.810
QALYs = quality-adjusted life-years; PANSS = Positive and Negative Syndrome
Scale; SF-36 = the 36-Item Short Form Health Survey; PCS = the Physical
Component Score; MCS = the Mental Component Score; FBS = family burden
scale of diseases.
Table 2 Average monthly costs by treatment group over
12 months







Direct medical costs 112.2(8.9) 107.5(9.2) 0.167 0.918
Medication costs 77.7(7.9) 79.2(8.1) 0.014 0.998
Intervention costs 6.9(1.7) 1.8(1.3) 7.837 0.005
Health care use costsa 25.7(3.9) 25.4(3.8) 0.141 0.707
Direct nonmedical costs 7.4(1.3) 6.5(1.4) 0.226 0.878
Indirect costs 94.7(14.0) 97.1(14.4) 0.007 0.999
Total costs 213.3(18.6) 213.2(19.2) 0.116 0.951
aExcluded intervention costs.
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gained), combined treatment could be considered a cost-
effective option compared to treatment as usual.
At the end of the study, 14.6 percent of patients in the
combined treatment group and 22.5 percent of patients
in treatment as usual group had relapsed (χ2 = 12.899,
df = 1, p < 0.001); readmission occurred in 6.5% of patients
in the combined treatment group and 11.2% of patients in
treatment as usual group (χ2 = 8.540, df = 1, p = 0.003).
Sensitivity analyses
Table 4 showed the details of the sensitivity analysis per-
formed. The combined treatment was always a dominant
strategy over treatment as usual.
Discussion
Schizophrenia is a very serious costly mental illness [1,2].
In this relatively large clinical trial of medication com-
bined psychosocial intervention for outpatients with early-






























Figure 2 Average monthly quality-adjusted life year rating.group had slightly higher QALYs than treatment as usual
group, but there were no statistically significant differen-
ces in medication costs or total health costs. These re-
sults were consistent with previous reports [27,28] in
which patients were treated with medication and psy-
chosocial intervention substantially increased health
gain with lower medical cost. The differences between
two groups in FBS total scores and SF-36 PCS and
MCS scores in present study further supports previ-
ous studies [6,7,27].
These results extend the efficacy and safety outcomes
analysis from the first report of the ESOS study, which
showed that patients with early-stage schizophrenia re-
ceiving combined medication and psychosocial interven-
tion had a lower rate of treatment discontinuation or
change, a lower risk of relapse, and improved insight,
quality of life, and social functioning compared with
those receiving treatment as usual [15]. Average monthly6 12
(months)
Table 4 Sensitivity analysis
Parameter Average CER (US $/QALY) ICER
Base case (BC) 14960 1819.4
Patients attendance per workshop
5 cases (−16% BC) 15144 2354.8
4 cases (−33% BC) 15422 3161.3
3 cases (−50% BC) 15882 4496.8
Cost per workshop
+20% BC 15093 2206.5
- 20% BC 14827 1432.3
Clinical effect
+20% BC 12467 1151.0
- 20% BC 18700 4338.5
QALYs = quality-adjusted life-years; CER = incremental cost effectiveness ratio;
ICER = incremental cost effectiveness ratio.
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treatment than treatment as usual, but no significant dif-
ferences were found in direct costs, indirect costs, and
total costs Individual payments play a huge role in the
current Chinese health care system. Patients with schizo-
phrenia have to stay at home to take medicine except for
hospitalization in mental hospital or seeing doctor in out-
patient in China [29].
Family caregivers experience significant burden in tak-
ing care of their patients with schizophrenia, and family
members may influence their relative's adherence with
medication and other treatment regimens [30]. In our
study, the family caregivers of patients assigned to com-
bined treatment reported less burden overall over 12
months than the caregivers of patients assigned to medi-
cation only treatment, suggesting that combined treat-
ment may decrease the family burden.
This study has several limitations. First, this was a
12-month trial; a longer-term randomized clinical trial
would contribute substantially to understanding cost-
effectiveness of psychosocial intervention on schizophre-
nia. Second, data loss from attrition was considerable.
More patients in medication group dropped out for
medication discontinuation or relapse than combined
treatment group. Partial compliance with antipsychotic
medication is associated with an increased risk of in-
patient hospitalization. As we all know, relapse and re-
hospitalization contribute significantly to the economic
burden of schizophrenia [9]. However, we did not con-
tinue to collect any information when medication dis-
continuation or clinical relapse happened, also did not
measure costs associated with relapse. This may be the
important reason why combined psychosocial inter-
vention was substantially more effective (using rates
of discontinuation for any cause as the measure ofeffectiveness), but slightly higher QALYs than medi-
cation treatment alone in present study. Third, we used
self-report for most of the measures. Self-report can be
vulnerable to recall bias. The self-report of medication
and care products for example, is often underestimated
[31]. Last, this study recruited only patients with early-
stage schizophrenia. Further prospective data monitoring
studies are needed to evaluate chronic schizophrenic pa-
tient costs.Conclusion
A combination of psychosocial interventions and medi-
cations has been highly recommended as a successful
treatment package for schizophrenia [6]. Despite there
were some limitations, present results confirmed that
combined intervention package was more cost-effective
than treatment as usual in early stage schizophrenia.
Future research is needed to evaluate the longer-term
effects on patient outcomes and consider broader mea-
sures of health care resource utilization.Additional files
Additional file 1: Protocol. Antipsychotic combination with psychosocial
intervention on the early-stage schizopherenia outcome study.
Additional file 2: The consort statement for cluster randomised
controlled trials.
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